Corrie Smith, NP
Nurse Practitioner · Greenwood, INNPI 1336927953
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,367 of the $16,665 with a category attached, or 80.2%. 30 manufacturers reported payments, led by Johnson & Johnson at 42.7% of the total. 2025 is the largest year on record at $14,469, more than ten times the $372 reported in 2023. Among nurse practitioner clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $142.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$7K
- Janssen Scientific Affairs, LLC$7K
- Medtronic$484
- Ferring Pharmaceuticals Inc.$306
- Bayer$269
- Pfizer$236
- plus $1K from 24 others
What the payments were for
- Consulting fees$13,36780%
- Travel & lodging$1401%
- Food & beverage$2,99718%
- Education$1611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $7,115 |
| Janssen Scientific Affairs, LLC | 7 | $6,856 |
| Medtronic | 19 | $484 |
| Ferring Pharmaceuticals Inc. | 3 | $306 |
| Bayer | 11 | $269 |
| Pfizer | 8 | $236 |
| Axonics, Inc. | 3 | $197 |
| Procept Biorobotics Corporation | 2 | $161 |
| Sumitomo Pharma America, Inc. | 5 | $108 |
| Coloplast | 5 | $99 |
| Novartis | 3 | $87 |
| Sun Pharmaceutical Industries Inc. | 4 | $84 |
| Urogen Pharma, Inc. | 3 | $67 |
| Astellas Pharma US Inc | 3 | $65 |
| Merck | 3 | $63 |
| Dendreon Pharmaceuticals LLC | 2 | $62 |
| AstraZeneca | 3 | $56 |
| Accord Healthcare, Inc. | 2 | $47 |
| Blue Earth Diagnostics | 2 | $40 |
| Progenics Pharmaceuticals, Inc. | 2 | $39 |
| Myriad Genetic Laboratories, Inc. | 2 | $32 |
| Tolmar, Inc. | 1 | $30 |
| Calyxo, Inc. | 1 | $29 |
| Abbott | 1 | $28 |
| Integra Lifesciences Corporation | 1 | $24 |
| Teleflex LLC | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
| Olympus America Inc. | 1 | $15 |
| Immunitybio, Inc. | 1 | $15 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADSTILADRIN$233
- AQUABEAM SYSTEM$137
- Erleada$121
- AKEEGA$121
- INTERSTIM$119
- Axonics$111
How this compares
$16,665 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 77 | $94,594 |
| MyrbetriqMirabegron | 24 | $24,889 |
| Mirabegron ErMirabegron | 11 | $7,846 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 178 | $3,444 |
| Trimethoprim | 55 | $2,831 |
| Estradiol | 28 | $1,742 |
| NitrofurantoinNitrofurantoin Macrocrystal | 51 | $1,384 |
| Tamsulosin Hcl | 126 | $1,243 |
| Cephalexin | 89 | $719 |
| Trospium Chloride | 19 | $686 |
| Ciprofloxacin Hcl | 73 | $410 |
| Doxycycline Hyclate | 12 | $382 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $263 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 60 | $236 |
| Fluconazole | 38 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $108 | $94,59477 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $24,88924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Greenwood
- Jeremy NivensGreenwood$12K
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
- Rhonda HettingerClarksville$38K
- Jennifer MaahsIndianapolis$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.